Physician profile
Cassandra Aesoph
NPI 1225698723
$425.07
in general payments reported to CMS, 2019-2025
11 companies · $166 in 2025
The $166 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $42.21 · 2022: $70.10 · 2023: $57.56 · 2024: $89.43 · 2025: $166.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $313.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $312.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alkermes, INC. | $138.79 | 2022-2025 | Lybalvi, Aristada |
| Abbvie INC. | $113.02 | 2021-2025 | Vraylar |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $35.97 | 2025 | Caplyta |
| Biohaven Pharmaceutical Holding Company LTD. | $24.48 | 2022 | |
| Janssen Pharmaceuticals, INC | $19.69 | 2024 | Invega Sustenna, Invega Trinza |
| Pfizer INC. | $17.06 | 2023 | |
| Exact Sciences Corporation | $16.62 | 2025 | Cologuard Collection Kit |
| Otsuka America Pharmaceutical, INC. | $15.86 | 2025 | Rexulti |
| Lilly USA, LLC | $15.57 | 2025 | Mounjaro |
| Neurocrine Biosciences, INC. | $14.68 | 2024 | Ingrezza |
| Organon LLC | $13.33 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Cassandra Aesoph listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.